Arvinas to Participate in Upcoming Investor Conferences

Key Takeaways:

• Arvinas is a clinical-stage biotechnology company focused on targeted protein degradation.
• It plans to speak at two major investor conferences: Guggenheim’s 2nd Annual Healthcare Innovation Conference and the Jefferies London Healthcare Conference.
• Guggenheim’s conference is scheduled for November 11.
• A live audio webcast of the presentation will be available through the company’s website.
• The announcement was distributed via Globe Newswire.

Participation in Upcoming Conferences

Arvinas, Inc. (NASDAQ: ARVN) recently confirmed that members of its management team will attend two key events in November: Guggenheim’s 2nd Annual Healthcare Innovation Conference on Tuesday, November 11, and the Jefferies London Healthcare Conference. Both conferences serve as important platforms for biotech and pharmaceutical companies to share updates on their latest research and development efforts.

Access to Live Webcasts

For interested investors and observers unable to attend in person, Arvinas has arranged a live audio webcast of its presentation during the Guggenheim conference. The company will host that webcast through its official website, with additional details available in the Events and Presentations section online.

Building on Targeted Protein Degradation

Based in New Haven, Connecticut, Arvinas is pioneering a new class of drugs based on targeted protein degradation. This approach harnesses the body’s natural protein disposal system to selectively eliminate disease-causing proteins, potentially offering innovative therapies for conditions that traditional small molecules struggle to address.

Looking Ahead

Arvinas’s participation in these conferences highlights continued momentum in its drug development programs. With multiple presentations on the horizon, the company is poised to showcase the progress of its clinical pipeline and invite investors to learn more about emerging therapies that could transform how diseases are treated. As Arvinas forges ahead, the scientific community eagerly awaits new data and developments stemming from these upcoming events.